Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets
Nektar Therapeutics (NKTR) has scheduled its Q3 2024 financial results announcement for Thursday, November 7, 2024, after U.S. market close. CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. The press release and audio webcast will be accessible through the company's website, with the webcast replay available until December 7, 2024. Pre-registration is required for conference call access.
Nektar Therapeutics (NKTR) ha programmato l'annuncio dei suoi risultati finanziari per il Q3 2024 per giovedì 7 novembre 2024, dopo la chiusura del mercato statunitense. Il CEO Howard Robin condurrà una conferenza telefonica alle 17:00 ET/14:00 PT per discutere i risultati. Il comunicato stampa e la webcasting audio saranno accessibili tramite il sito web dell'azienda, con la registrazione della webcasting disponibile fino al 7 dicembre 2024. La registrazione anticipata è necessaria per accedere alla conferenza telefonica.
Nektar Therapeutics (NKTR) ha programado el anuncio de sus resultados financieros del Q3 2024 para el jueves 7 de noviembre de 2024, después del cierre del mercado estadounidense. El CEO Howard Robin realizará una conferencia telefónica a las 5:00 p.m. ET/2:00 p.m. PT para discutir los resultados. El comunicado de prensa y la transmisión de audio estarán disponibles a través del sitio web de la empresa, con la repetición de la transmisión disponible hasta el 7 de diciembre de 2024. Se requiere preinscripción para acceder a la conferencia telefónica.
Nektar Therapeutics (NKTR)는 2024년 11월 7일 목요일에 2024년 3분기 재무 결과 발표를 예정하고 있으며, 미국 시장 마감 후에 진행합니다. CEO Howard Robin이 오후 5시 ET/오후 2시 PT에 결과에 대해 논의하는 전화 회의를 주관할 예정입니다. 보도 자료와 오디오 웹캐스트는 회사 웹사이트를 통해 접근할 수 있으며, 웹캐스트 재방송은 2024년 12월 7일까지 이용 가능합니다. 전화 회의 접근을 위해 사전 등록이 필요합니다.
Nektar Therapeutics (NKTR) a prévu l'annonce de ses résultats financiers du Q3 2024 pour le jeudi 7 novembre 2024, après la clôture des marchés aux États-Unis. Le PDG Howard Robin animera une conférence téléphonique à 17h00 ET/14h00 PT pour discuter des résultats. Le communiqué de presse et la diffusion audio seront accessibles via le site Web de l'entreprise, avec un enregistrement de la diffusion disponible jusqu'au 7 décembre 2024. Une préinscription est requise pour accéder à la conférence téléphonique.
Nektar Therapeutics (NKTR) hat die Bekanntgabe seiner Finanzergebnisse für das Q3 2024 auf Donnerstag, den 7. November 2024, nach Börsenschluss in den USA, angesetzt. CEO Howard Robin wird um 17:00 Uhr ET/14:00 Uhr PT eine Telefonkonferenz leiten, um die Ergebnisse zu besprechen. Die Pressemitteilung und die Audio-Webcast werden über die Website des Unternehmens zugänglich sein, mit einer Wiederholung des Webcasts bis zum 7. Dezember 2024. Eine Voranmeldung ist erforderlich, um an der Telefonkonferenz teilzunehmen.
- None.
- None.
The press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 7, 2024.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Our pipeline also includes a preclinical candidate NKTR-0165, which is a bivalent tumor necrosis factor receptor type II agonist antibody. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contacts:
For Investors:
Vivian Wu of Nektar Therapeutics
(628) 895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-to-announce-financial-results-for-the-third-quarter-2024-on-thursday-november-7-2024-after-close-of-us-based-financial-markets-302293320.html
SOURCE Nektar Therapeutics
FAQ
When will Nektar (NKTR) release Q3 2024 earnings?
What time is Nektar's (NKTR) Q3 2024 earnings call?
How long will Nektar's (NKTR) Q3 2024 earnings call replay be available?